Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, L
Right arrow Articles by Clark, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L
Right arrow Articles by Clark, R.
Haematologica, Vol 91, Issue 2, 235-239
Copyright © 2006 by Ferrata Storti Foundation

Journal Article

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia

L Wang, K Knight, C Lucas, and RE Clark

Department of Haematology, Royal Liverpool University Hospital, Prescot St, Liverpool L7 8XP, United Kingdom.

BCR-ABL kinase mutations may confer resistance to imatinib in patients with chronic myeloid leukemia (CML), and may predict a poor outcome. We investigated whether rises in BCR-ABL transcript levels predicted mutation development in 82 CML patients receiving imatinib. Eleven mutations were detected in 10 patients. A single 2-fold or greater rise in BCR-ABL transcript did not predict mutations. However, a mutation was detectable in five of six cases with progressively rising levels of transcripts. In contrast, consecutive rises were not seen in any of 33 stable responders. Rising BCR-ABL transcript levels can identify patients who developBCR-ABLmutations. A serial rise is more reliable than a single rise.


This article has been cited by other articles:


Home page
 haematolHome page
T. Lundan, V. Juvonen, M. C. Mueller, S. Mustjoki, T. Lakkala, V. Kairisto, A. Hochhaus, S. Knuutila, and K. Porkka
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia
Haematologica, February 1, 2008; 93(2): 178 - 185.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Haematologica, February 1, 2008; 93(2): 186 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
G. Saglio, F. Pane, and G. Martinelli
State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia
ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Clin. Cancer Res., October 15, 2007; 13(20): 6136 - 6143.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
R. D. Press, S. Willis, C. Rempfer, M. J. Mauro, B. J. Druker, and M. W.N. Deininger
A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.
Blood (ASH Annual Meeting Abstracts), November 1, 2006; 108(11): 2152 - 2152.
[Abstract] [PDF]

Home page
 ASH Education BookHome page
M. J. Mauro
Defining and Managing Imatinib Resistance
Hematology, January 1, 2006; 2006(1): 219 - 225.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.